Cost Savings Achieved through Introduction of HOLEP and Care Pathway

Andrew Lai MPH
USF MCOM- LVHN Campus

Benjamin Croll
USF MCOM- LVHN, Benjamin.Croll@lvhn.org

Rohan Shah BS
Rohan.Shah@lvhn.org

Jacob Rust BS
Jacob.Rust@lvhn.org

Angelo A. Baccala Jr MD, MBA
Lehigh Valley Health Network, angelo_a.baccala@lvhn.org

See next page for additional authors

Follow this and additional works at: https://scholarlyworks.lvhn.org/select-program

Part of the Medical Education Commons

Published In/Presented At
Authors
Andrew Lai MPH; Benjamin Croll; Rohan Shah BS; Jacob Rust BS; Angelo A. Baccala Jr MD, MBA; and James Johannes MD

This poster is available at LVHN Scholarly Works: https://scholarlyworks.lvhn.org/select-program/208
Background

- 50% of men between ages 51-60 will develop benign prostatic hyperplasia (BPH)
- Holmium Laser Enucleation of the Prostate (HOLEP) was introduced as a safer and more efficacious surgical technique compared to the gold-standard transurethral resection of the prostate (TURP)
- HOLEP is generally performed in high-volume academic institutions due to the steep procedural learning curve and high capital costs to the institution
- Lehigh Valley Health Network (LVHN) is a large community-based institution that established a HOLEP program and care pathway at lowering the costs of surgical treatment for BPH, but its effectiveness has not been measured
- This pilot study’s objective is to investigate the impact on length of stay (LOS) as a source of cost savings compared to TURP in this community-hospital setting

Problem Statement

Can we shorten the length of stay through implementation of care pathway in HOLEP vs traditional TURP procedure, thereby lowering cost of BPH treatment, without significant differences in post-operative outcomes?

Methods

All patients undergoing HOLEP and TURP between August 6, 2015, to September 20, 2017, were identified and included in this pilot retrospective cohort study. The study protocol was approved a priori by the LVHN Institutional Review Board. The primary outcome was total hospital length of stay (LOS). Secondary outcomes were total cost, volume of tissue resected, and 6- and 12-week post-operative changes in maximum urine flow rate (Qmax), post-void residual (PVR), International Prostate Symptom Score (IPSS), and Bother Score. Data were collected independently among 4 investigators from review of electronic medical records (EMR) using standardized forms and analyzed with analysis of variance using SAS 9.4.

Results

- In this study, 51 HOLEP and 155 TURP patients were identified.
- On average, HOLEP patients had a LOS that was 11.9 hours shorter than TURP patients (95% CI 4.08 to 19.7; p=0.003) and saved $267.44 in hospital charges (95% CI -$2.60 to $537.49; p=0.0522; Table 1)
- At 6-weeks follow-up, HOLEP patients experienced a larger improvement in Qmax (6.9 vs 2.1ml/s; p=0.013), decrease in PVR (-263 vs -115ml; p=0.0009), IPSS (-7.0 vs 6.2; p=0.7655), and Bother Score (-1.3 vs -1.13; p=0.7587) compared to TURP patients (Table 2)
- At 12-weeks follow-up, HOLEP patients experience a larger improvement in Qmax (7.1 vs 2.9ml/s; p=0.0582), decrease in PVR (-264 vs -118ml; p=0.0007), and IPSS (-9.4 vs -9.0; p=0.9010), while TURP patients experienced a greater decrease Bother Score (-2.0 vs -2.3; p=0.6580; Table 2)
- HOLEP patients had higher prostatic volume resected (41.5g vs 16.5; p=0.0003)

Problem Statement

Can we shorten the length of stay through implementation of care pathway in HOLEP vs traditional TURP procedure, thereby lowering cost of BPH treatment, without significant differences in post-operative outcomes?

Table 1. Mean (±Standard Deviation) Length of Stay and Cost Savings

<table>
<thead>
<tr>
<th></th>
<th>HOLEP (n = 51)</th>
<th>TURP (n = 155)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Length of Stay (hrs)</td>
<td>8.20 (±8.84)</td>
<td>20.10 (±27.84)</td>
<td>p=0.0030</td>
</tr>
<tr>
<td>Cost of Care</td>
<td>$1766.57 (±$507.38)</td>
<td>$2034.01 (±$933.38)</td>
<td>p=0.0522</td>
</tr>
</tbody>
</table>

Table 2. Procedural Outcomes Between HOLEP and TURP Patients at 6- and 12-Week Follow-Up

<table>
<thead>
<tr>
<th></th>
<th>6-Week Follow-Up</th>
<th>12-Week Follow-Up</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HOLEP</td>
<td>TURP</td>
</tr>
<tr>
<td>Change in Qmax (ml/s)</td>
<td>6.9</td>
<td>2.1</td>
</tr>
<tr>
<td>Change in Post-Void Residual (ml)</td>
<td>-263</td>
<td>-115</td>
</tr>
<tr>
<td>Change in IPSS</td>
<td>-7.0</td>
<td>-6.2</td>
</tr>
<tr>
<td>Change in Bother Score</td>
<td>-1.3</td>
<td>-1.13</td>
</tr>
</tbody>
</table>

Conclusions and Future Implications

In this setting, HOLEP patients experienced shorter LOS and lower costs while reporting overall improved post-operative outcomes compared to TURP patients. This must be interpreted with caution, as the largest limitation to this study was incomplete data in the EMR. Many patients were lost to follow-up, possibly due to significantly improved symptoms, which highlights selection bias in the study. Prospective studies at LVHN are needed with strict patient follow-up to determine a more accurate relative impact of HOLEP.